Wayfinding Financial, LLC Eli Lilly & CO Transaction History

Wayfinding Financial, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$724.87 - $909.04 $13,772 - $17,271	-19 Reduced 1.71%	1,094 $990,000
Q1 2024 May 09, 2024	BUY	$592.2 - $792.28 $45,007 - $60,213	76 Added 7.33%	1,113 $865,000
Q4 2023 Jan 09, 2024	BUY	$525.19 - $619.13 $115,541 - $136,208	220 Added 26.93%	1,037 $604,000
Q3 2023 Nov 02, 2023	SELL	$434.7 - $599.3 $44,339 - $61,128	-102 Reduced 11.1%	817 $438,000
Q2 2023 Jul 31, 2023	SELL	$350.74 - $468.98 $8,768 - $11,724	-25 Reduced 2.65%	919 $430,000
Q1 2023 May 04, 2023	BUY	$310.63 - $364.82 $293,234 - $344,390	944 New	944 $324,000
Q3 2022 Nov 08, 2022	BUY	$296.48 - $337.87 $11,266 - $12,839	38 Added 5.85%	688 $222,000
Q2 2022 Aug 09, 2022	BUY	$278.73 - $327.27 $181,174 - $212,725	650 New	650 $210,000

4,004

752M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $711B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Wayfinding Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Wayfinding Financial, LLC with notifications on news.